The incidence and severity of influenza infections vary from year to year, and obtaining the annual influenza vaccine remains the best approach to reducing the incidence of severe infections, hospitalization, influenza-related complications, and death. Recently, the CDC issued clinical practice recommendations for the upcoming 2022-2023 influenza season, including the use of four FDA-approved antiviral drugs for the treatment and prevention of influenza. Pharmacists are well poised to educate patients about influenza, including modes of transmission, clinical presentation, and available treatments; they can also give patients pertinent information regarding factors that confer a greater risk of influenza-related complications and suggest measures to prevent or lessen the severity of these infections.
展开▼
